Investment in Evofem Narrative (Details) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) $ / shares	Sep. 30, 2018 USD ($)	Jun. 10, 2019 USD ($) $ / shares shares	Apr. 11, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($)
Debt and Equity Securities, FV-NI [Line Items]
Investment Owned, at Cost	$ 6,600		$ 6,600				$ 6,600
Gain (Loss) on Investments	3,476	$ 0	3,476	$ 0
Unrealized Gain (Loss) on Investments	(27,378)	$ 0	18,109	$ 0
Evofem [Member]
Debt and Equity Securities, FV-NI [Line Items]
Investment Owned, at Cost	$ 60,000		$ 60,000
Tranche 1 of investment						$ 30,000
Investment Owned, Balance, Shares | shares						6,666,667
Warrants acquired | shares					1,666,667	1,666,667
Board member appointed					1
Board observer appointed					1
Warrants and Rights Outstanding, Term						7 years
Shares acquired | shares					6,666,667
Investment Warrants, Exercise Price | $ / shares			$ 6.38
Tranche 2 of investment					$ 30,000
Cost of tranche two investment option, per share | $ / shares					$ 4.50	$ 4.50
Investment ownership percentage	29.00%		29.00%
Common Stock [Member] | Evofem [Member]
Debt and Equity Securities, FV-NI [Line Items]
Unrealized Gain (Loss) on Investments	$ (21,400)		$ 16,600
Warrant [Member] | Evofem [Member]
Debt and Equity Securities, FV-NI [Line Items]
Gain (Loss) on Investments	$ (6,000)		$ 1,500